Hypoxic-ischemic (HI) brain injury is recognized as a significant problem in the perinatal period, contributing to life-long language-learning and other cognitive impairments. Central auditory processing deficits are common in infants with hypoxic-ischemic encephalopathy and have been shown to predict language learning deficits in other at risk infant populations. Inter-alpha inhibitor proteins (IAIPs) are a family of structurally related plasma proteins that modulate the systemic inflammatory response to infection and have been shown to attenuate cell death and improve learning outcomes after neonatal brain injury in rats. Here, we show that systemic administration of IAIPs during the early HI injury cascade ameliorates complex auditory discrimination deficits as compared to untreated HI injured subjects, despite reductions in brain weight. These findings have significant clinical implications for improving central auditory processing deficits linked to language learning in neonates with HI related brain injury.
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Introduction
Perinatal hypoxic-ischemic (HI) brain injury, prematurity, verylow-birth-weight (VLBW <1200 g) and infectious disorders often place neonates at high risk for developmental language delays (Vohr, 2014 (Vohr, , 2016 . Central auditory processing deficits have been reported to contribute to later language delays similar to delays observed in children with language learning impairments of unknown origin (Ortiz-Mantilla et al., 2008) . Previous work has consistently reported an association between complex and/or rapid auditory processing impairments and later language outcomes in young children (Benasich and Tallal, 2002) . Further, infant auditory temporal processing thresholds for the discrimination of rapidly presented tone-pairs are highly predictive of the age at which language commences in both typical and at risk infants (Benasich and Tallal, 2002; Cantiani et al., 2016) . Likewise, experimental models in neonatal rodents after exposure to unilateral HI brain injury exhibit complex central auditory processing deficits and injury profiles similar to those observed in human full term and premature infants with brain injury (Downie et al., 2002; McClure et al., 2006a,b; McClure et al., 2007) .
Currently, hypothermia is the only approved therapy to attenuate brain damage in infants, but is only partially protective and can only be used in the presence of HI encephalopathy (HIE) in full term infants (Gunn et al., 1997; Shankaran et al., 2005; Gluckman et al., 2006) . Despite efforts to develop additional therapeutic strategies, there are currently no pharmacological agents available to treat human neonates at risk for brain injury (McClure et al., 2006a,b; McClure et al., 2007; Xiong et al., 2011) . Nonetheless, recent work has suggested a critical role for inflammation and immune reactivity in regulating the injury cascade after exposure to HI in neonates (Dammann and Leviton, 1997; Becker, 1998; Ferriero, 2004; Iadecola and Anrather, 2011) .
Inter-alpha inhibitor proteins (IAIPs) are a family of structurally related serine protease inhibitors with immune modulating capabilities that have been shown to down-regulate proinflammatory cytokines, Interleukin (IL)-1b and Tumor Necrosis Factor (TNF)-a and upregulate anti-inflammatory cytokine IL-10, leading to improved outcomes in several different models of systemic inflammatory disorders (Baek et al., 2003; Wakahara et al., 2005; Chen et al., 2016 
